Evidence map›Paper›PMID 41269378›Full record

ArticleBreast cancer research and treatment2025

Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study.

Kathryn E Post, Laura Dunderdale, Shibani Datta, Leticia Varella, Nora Horick, Lara Traeger, Joseph A Greer, Beverly Moy, Jennifer S Temel, Jamie M Jacobs

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kathryn E PostMassachusetts General Hospital, Boston, MA, USA. kepost@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-1777-5158
Laura DunderdaleMassachusetts General Hospital, Boston, MA, USA.
Shibani DattaYeshiva University, New York, NY, USA.
Leticia VarellaHarvard Medical School, Boston, MA, USA.
Nora HorickMassachusetts General Hospital, Boston, MA, USA.
Lara TraegerSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Joseph A GreerMassachusetts General Hospital, Boston, MA, USA.
Beverly MoyMassachusetts General Hospital, Boston, MA, USA.
Jennifer S TemelMassachusetts General Hospital, Boston, MA, USA.
Jamie M JacobsMassachusetts General Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUp to 30% of patients with hormone receptor-positive (HR +) breast cancer do not start adjuvant endocrine therapy (AET) as prescribed. AET non-initiation is associated with increased recurrence and decreased survival. We conducted a single-arm, open-pilot study to assess the feasibility and acceptability of a nurse-led, culturally sensitive intervention ('INITIATE') to optimize AET initiation.

methodsFrom 9/2022 to 8/2024, we recruited 35 patients with stage I-IIIB, HR + breast cancer who delayed or reported hesitancy to start AET. INITIATE included two virtual sessions delivered in English or Spanish with an oncology nurse. Feasibility was defined by enrollment rates (> 50% eligible patients), intervention attendance (≥ 70% of patients attending one of two sessions), and retention (> 70% completing the 3-month questionnaire). At baseline, 1 month, and 3 months post-baseline, patients self-reported sociodemographics, AET initiation, intervention acceptability (Client Satisfaction Questionnaire-3), and other psychosocial outcomes. We conducted semi-structured, qualitative exit interviews to gather additional feedback. We computed descriptive statistics for the quantitative outcomes and conducted a rapid qualitative analysis of the interview data.

resultsWe enrolled 45.5% (35/77) of eligible patients; 82.9% (29/35) attended at least one intervention session, and 77.1% (27/35) completed the 3-month assessment. Most patients (68.6%) were White, and 37.1% identified as a racial or ethnic minority. Qualitatively, patients reported that INITIATE helped them understand the importance of taking AET and improved their coping skills. Ninety-six percent reported high acceptability, and 88.9% started their AET by three months post-baseline.

conclusionINITIATE is mostly feasible and acceptable and demonstrates promise for promoting AET initiation among patients with HR + breast cancer.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsAdultAgedChemotherapy, AdjuvantFeasibility StudiesFemaleHumansMiddle AgedPilot ProjectsAntineoplastic Agents, HormonalAdjuvant endocrine therapyBreast cancerEndocrine therapy initiationPilot study

Identifiers

PMID41269378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.